Review top news and interview highlights from the week ending September 15, 2023.
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Adstiladrin was approved in December 2022 and is now available for select patients under an Early Experience Program.
The chief research officer, Muscular Dystrophy Association, shared a message for Duchenne Action Month.
Novartis stated that the decision was made in light of a recommendation from an independent data monitoring committee.
The head of the Pediatric Neurology Fellowship Program at the University of Valparaíso in Chile discussed positive impact of newborn screening so far and work that still needs to be done.
The company also announced its plans for a modified study protocol that may allow a roadway to approval.
Will the CMS CGT Model Support Patient Access to Sickle Cell Disease CGTs?
July 25th 2024Cell and gene therapies can transform the paradigm of care for patients with chronic, complex conditions, but these therapies come at an up-front cost of several million dollars per treatment, complicating the pipeline of access to them.